Psoriatic Drugs

Core Concepts

The immune engine behind psoriasis

Psoriasis is driven by T cells — white blood cells that, in psoriasis, become inappropriately activated and travel to the skin. There they release signaling proteins (cytokines), especially the interleukin-23 (IL-23) → IL-17 axis, which push keratinocytes to divide rapidly and trigger inflammation. The visible result — thick scale over red skin — is a footprint of this immune signal. This is why the newest therapies are not creams that peel skin but biologics that intercept specific cytokines: block the signal, and the skin's overgrowth slows. It also explains a famous exam point: psoriasis is not primarily a skin-cell disease; it is an immune disease with skin manifestations.

Topical corticosteroids: potency is the key concept

Corticosteroids are the workhorse of topical psoriasis therapy. They work by broad anti-inflammatory and immunosuppressive effects — dampening the immune signal and calming the redness and scaling. What nurses must understand is potency classes: topical steroids are ranked from very low to very high potency (Class VII to Class I in the common US ranking). High-potency products are more effective but carry more risk — skin thinning (atrophy), striae, and greater absorption — so they are used cautiously, on limited areas, for limited courses. Low-potency products are chosen for sensitive sites like the face, groin, and skinfolds. Potency, site, and duration are prescriber decisions; the nurse's job includes assessing the skin, applying or teaching correct application, and watching for local effects like thinning or irritation.

Vitamin D analogs: a different lever

Vitamin D analogs such as calcipotriene (calcipotriol) slow keratinocyte proliferation and normalize their maturation — they attack the "skin cells divide too fast" problem directly. They are frequently combined with topical corticosteroids: the steroid quiets inflammation fast, the vitamin D analog addresses the abnormal cell turnover, and the combination often works better than either alone. They can irritate skin, and overuse on large areas can affect calcium balance — a class-level caution that matters for nursing monitoring and teaching. Note the distinction: a vitamin D analog used on the skin for psoriasis is a drug, not a dietary supplement.

Other topical options

Tazarotene is a topical retinoid that normalizes keratinocyte growth; like other retinoids it irritates and photosensitizes skin. Coal tar and anthralin are older agents that slow cell turnover and reduce scaling; they are effective but messy, staining skin and clothing, which affects adherence. The pattern across all topicals: they work where applied, they are safe relative to systemic drugs, and their practical limits (mess, irritation, time) drive people toward systemic options when disease is extensive.

Phototherapy: UV light as treatment

Ultraviolet light suppresses the immune activity in psoriatic skin. Narrowband UVB is the most common form. PUVA combines a photosensitizing drug (psoralen, taken or applied) with UVA exposure. Phototherapy is effective for widespread psoriasis and avoids systemic immunosuppression, but it requires repeated visits and carries cumulative skin-cancer and photoaging risks over a lifetime — so total exposure is tracked.

Systemic drugs: methotrexate, cyclosporine, acitretin

When psoriasis is extensive, disabling, or involves joints, systemic therapy begins:

• Methotrexate inhibits folate-dependent enzymes, interfering with immune-cell replication — an immunosuppressant that calms the immune drive of psoriasis. It requires monitoring (including blood counts and liver function), and folic acid supplementation is part of the usual plan.
• Cyclosporine is a calcineurin inhibitor that blocks T-cell activation — fast and effective but reserved for shorter-term control because of its effects on blood pressure and kidney function, which require monitoring.
• Acitretin is an oral retinoid that normalizes keratinocyte growth. It is teratogenic and persists in the body for a long time after stopping, so pregnancy must be avoided for an extended period — a major nursing-education point. It also dries mucous membranes and skin.

All three are powerful drugs with real toxicity; the theme for exams and practice is the same: the more systemic the therapy, the more monitoring and teaching the nurse owns.

Biologics: precision immunosuppression

Biologics are proteins (often monoclonal antibodies) that block specific cytokines or their receptors. In psoriasis, current classes include TNF inhibitors (e.g., etanercept, infliximab, adalimumab), IL-17 inhibitors (e.g., secukinumab, ixekizumab), IL-12/23 inhibitors (e.g., ustekinumab), and IL-23 inhibitors (e.g., guselkumab, risankizumab). They give dramatic clearance of plaques in many people. The trade-off is systemic immunosuppression: infection risk rises, and guidelines require tuberculosis screening before starting (latent TB can reactivate). Most are given by injection or infusion, so nurses are deeply involved — preparing, administering, observing for infusion/injection reactions, teaching about infection signs, and coordinating the screening work-up.

Common Confusions